期刊文献+

动静脉不同给药途径新辅助化疗治疗局部晚期宫颈癌临床对比 被引量:9

原文传递
导出
摘要 目的对比局部晚期宫颈癌新辅助化疗经子宫动脉灌注化疗栓塞和静脉化疗两种途径的临床疗效及不良反应,以寻求更安全、有效的新辅助化疗途径。方法将我院自2006年至2011年收治的60例子宫颈癌Ib2-IIb期患者分为两组,其中A组(子宫动脉灌注化疗栓塞组)28例,B组(静脉化疗组)32例,观察并对比两组的临床疗效及不良反应。结果A、B两组阴道切缘阳性率、宫旁阳性率、脉管浸润率、淋巴结阳性率比较差异均无统计学意义(P均〉0.05);A组局部病灶缩小有效率(92.86%)明显高于B组(71.88%)、A组宫颈深层问质浸润率(7.14%)明显低于B组(33.33%)(x2值分别为4.391、6.054,P均〈0.05)、A组化疗胃肠道反应发生率(53.57%)明显低于B组(92.16%)、A组骨髓抑制率(46.43%)明显低于B组(82.35%),两组比较差异有统计学意义(妒值分别为15.935、11.030,P均〈0.05)。结论局部晚期宫颈癌术前采用静脉化疗简单易行,但不良反应较大;动脉化疗栓塞对改善局部肿瘤浸润,提高手术切净率更有优势,不良反应轻,有条件者可选择动脉给药新辅助化疗。
作者 蒋瑜
出处 《中国综合临床》 2013年第10期1098-1100,共3页 Clinical Medicine of China
  • 相关文献

参考文献7

二级参考文献74

  • 1王平,彭芝兰,张家文,刘辉,张崇淑,曹泽毅.子宫颈癌新辅助化疗中不同化疗途径的疗效比较[J].中华妇产科杂志,2005,40(4):227-230. 被引量:109
  • 2陈春林,谭道彩,梁立治.动、静脉灌注化疗子宫颈癌组织药物浓度的比较[J].中华妇产科杂志,1995,30(5):298-298. 被引量:172
  • 3谭玉婷,林仲秋,陈勍,冯华英,张丙忠.以卡铂为基础的32例宫颈癌新辅助化疗的临床观察[J].中国妇产科临床杂志,2006,7(4):245-247. 被引量:7
  • 4Strecker EP,Heber R,Boos I,et al.Preliminary experience with locoregional intraarterial chemotherapy of uterine cervical or endometrial cancer using the peripheral implantable port system (PIPS):a feasibility study[J].Cardiovasc Intervent Radiol,2003,26(2):118-120.
  • 5Kobayashi K,Furukawa A,Takahashi M,et al.Neoadjuvant intra-arterial chemotherapy for locally advanced uterine cervical cancer:clinical efficacy and factors influencing response[J].Cardiovasc Intervent Radiol,2003,26(3):234-241.
  • 6Loneastor JA, CoPer KA, Logue JP, et al. Vascular endothelial growth factor (VEGF) expression prognostic factor for radio therapyouteomcin advanced carcinoma of the cervix[ J]. British Jounal of Cancer, 2005,83 (5) :620-622.
  • 7Bryant P, Zheng Q, Pumiglia K. Focal adhesion kinasecontrols cellular levels of MVD through Skp2-dependent and-independent mechanisms [J]. Mol Cell Bio, 2006, 26(2) : 4201-4204.
  • 8Aalma L, Ludwig E, Huber A, et al. Serum vaseular endothelial growth factor and serum leptin in patient with cervical cancer[ J]. Gynecol Oncol, 2004, 85(1) :3235-3238.
  • 9Tjalma W, Weyler J, Weyn B, et al. The aesociation between vascular endothelial growth factor microvessel density and clinicopathological, featurcin invasive cervical cancer[ J]. Eur J Obstet Gynecol Reprod Biol, 2004, 92(2) :251-252.
  • 10Suzuki T, Urano T, Miki Y, et al. Vascular endothelial growth factor (VEGF) in human breast carcinoma as a potent prognostic factor[J]. Cancer Sci, 2007, 98(2): 644-648.

共引文献121

同被引文献90

  • 1朱朝勇,李志燕,郭生梅,吴德慧,王烈宏.FP与TP方案在早期高危宫颈癌术后同步放化疗中的有效性和安全性的临床研究[J].青海医药杂志,2012,42(4):5-7. 被引量:6
  • 2刘翼.子宫颈癌新辅助化疗不同给药途径对疗效的影响[J].实用癌症杂志,2014,29(3):308-310. 被引量:13
  • 3陈对梅,王峻,牛金亮,郑英.MRI评估宫颈癌宫旁侵犯和淋巴结转移的价值[J].中国医学影像技术,2009,25(S1):138-140. 被引量:14
  • 4孙燕,石远凯.内科肿瘤学[M].北京:人民卫生出版社,2007:785-788.
  • 5Vandecasteele K, Makar A, Van den Broecke R, et al. In- tensity- modulated arc therapy with cisplatin as neo - adju- vant treatment for primary irresectablecervical cancer. Toxic- ity, tumour response and outcome[ J ]. Strahlenther Onkol,2012, 188(7): 576.
  • 6Islam S, Mukhopadhyay L, Howells R. Neo- adjuvant chemotherapy and radical surgery for stage 1B cervical cancer in pregnancy[J]. J Obstet Gynaecol, 2012, 32(2) : 191.
  • 7Zanaboni F, Grijuela B, Giudici S, et al. Weekly topotecan and cisplatin (TOPOCIS) as neo - adjuvant chemotherapy for locally- advanced squamous cervical carcinoma: Results of a phase Ⅱ multicentric study[J]. Eur J Cancer, 2013, 49(5): 1065.
  • 8Fanfani F, Fagotti A, Gagliardi M L, et al. Pre- hysterec- tomy cone biopsy is able to predict response in locally ad- vanced cervical cancer patients submitted to neo - adjuvant cbemoradiation[J]. Eur J Surg Oncol, 2013, 39(9) : 1025.
  • 9Singh R B, Chander S, Mohanti B K, et al. Neoadjuvant chemotherapy with weekly paclitaxel and carboplatin followed by chemoradiation in locally advanced cervical carcinoma: a pilot study[J]. Gynecol Oncol, 2013, 129(1): 124.
  • 10艾恒玲.宫颈癌及癌前病变相关危险因素分析[J].中国药物经济学,2013,(4):324-325.

引证文献9

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部